Skip to main content
European Commission logo
European Assistance for Innovation Procurement (EAFIP)

Big Data for Personalised Medicine (MEDP-BIG DATA) - Gobierna de Canarias

Logo-Gobierno-de-Canarias

Information about the procurement

ICT Solution: Big Data for Personalised Medicine (MEDP-BIG DATA)

MEDP-BIG DATA aimed to improve diagnosis, treatment and research in chronic, oncological, degenerative and rare diseases, either for emergencies or flow management, through personalised medicine with new tools of BigData. The system serves as a support to clinical decisions oriented to each individual patient including the support of assisted autoanamnesis by facilitating algorithms.

The project provides the Health Services of the Canary Islands, Andalusia and Valencia with instruments that allow them to make health decisions adapted to the characteristics and individual needs of each patient. Clinical, pathological, image, prognostic and predictive variables, like other non-clinical and available outside the health system (style of life, adherence to treatment, etc.) were considered.

The solution(s) integrate data from various sources, and facilitate its analysis and exploitation, making it possible to determine patterns of evolution of the disease, therapeutic response, etc. It is focused towards the management of these diseases with criteria of opportunity, effectiveness, efficiency, feasibility and sustainability of assistance health.

Key technologies:

Project picture_Canarias_MEDP-Big-Data
  • Artificial Intelligence, machine learning and predictive models
  • Virtual patient assistant for diagnosis, simple treatment, extension of reports and personalised health.
  • Management of large volumes of Data
  • Analytics using open data (text mining, datamining, statistical, predictive and descriptive models)
  • Clinical data quality evaluation
  • Interoperability and security of big data services in health and research repositories
  • Predictions by similarity of clinical routes
  • Aggregate medical evidence through decision theory
  • Multi-criteria stratification of patients
  • Early and quantitative treatment evaluation
  • Interrogation to repositories through abstractions


Public Procurer:  Gobierna de Canarias / Government of the Canary Islands

Type of innovation procurement:  Pre-Commercial Procurement  – PCP

Timeframe: Start of project September 2019. 
Contract for Phase 1 of the PCP awarded April 2022. 

Budget invested by the procurer: € 6.000.000,-

 

Market consultation:


More information:

Specifications document: https://www3.gobiernodecanarias.org/sanidad/scs/content/117f42e7-15fb-11ec-ac5b-0be862e149d7/Documento-informativo-anuncio-previo-MedP-08-09-21.pdf

Tender documents: DOC_CD2021-712051.pdf (contrataciondelestado.es)

Website Gobierno de Canarias: FID Salud Program (promotion of innovation from the demand side)

Contract notice (published 8 September 2021): 

The contract was awarded (05/04/2022) to 3 companies for Phase 1 of the PCP:

  • GMV SOLUCIONES GLOBALES INTERNET, S.A.U: total of 417.888,81 euros for Phase 1
  • UTE18/CPP1 QWERTY – LABERIT: total of 418.264,66 euros for Phase 1
  • VIRTUAL DOCTOR AND MEDICINES, S.L.: total de 313.697,70 euros for Phase1.

More information contract award Phase 1: https://contrataciondelestado.es/wps/wcm/connect/dd2b7a53-105c-41c8-9599-875cea1cd026/DOC20220406133906Orden+Adj++18+CPP+f.pdf?MOD=AJPERES

Newsitems on the results of the project:

Infoday_bre-Medicina-Personalizada-BigData_eCuidat

EAFIP Assistance provided

To the specific tender:
Support throughout the preparation phase and the drafting of tender documents.

To the general procurement of the organisation:
Best practices for innovation procurement, development of a business case and contract management.

CURRENT STATUS - Completed project

The project completed Phase 1 successfully in 2022 (contract awarded in April 2022 for Phase 1 of the PCP). 
In 2023, the Tenerife Ethics Committee for Research with Medicines approved the extension of the study to ten new use cases (UC) that address different aspects of assumptions corresponding to various pathologies. These 10 use cases entered Phase 2 of the PCP.  Phase 2 - Piloting and testing was launched in December 2022. Results of the piloting work in Phase 2 were presented in June 2023. 

The final PCP phase (“phase 3”) delivered:

  • Operational digital tools (Cuidat‑e)
  • AI applications tested in real healthcare settings
  • Validated use cases and datasets
  • Evidence base for personalised medicine in public systems

By 2026, the project has moved beyond prototyping to become a strategic platform enabling future deployment and precision medicine programmes.

Overall
The Big Data and Personalised Medicine PCP successfully delivered and validated a suite of AI-based digital health solutions under the Cuídat‑e ecosystem, demonstrating the feasibility and clinical value of personalised, data-driven healthcare in real settings. The project produced functional prototypes including patient monitoring apps, predictive analytics for hospitalisation risk, AI-supported diagnostics (e.g. imaging and rare disease detection), and automated clinical tools such as pre-consultation and voice-to-text systems, achieving strong performance and improving efficiency in care delivery. Overall, the PCP proved both the technical viability and healthcare impact of integrating AI into clinical workflows.